Clinical Trials Logo

Clinical Trial Summary

The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of melanoma.


Clinical Trial Description

By enrolling patients with small metastases of melanoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of high-activity natural killer cells.

The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03007823
Study type Interventional
Source Fuda Cancer Hospital, Guangzhou
Contact
Status Completed
Phase Phase 1/Phase 2
Start date December 1, 2016
Completion date June 1, 2019

See also
  Status Clinical Trial Phase
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Active, not recruiting NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Recruiting NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Recruiting NCT02854488 - Yervoy Pregnancy Surveillance Study N/A
Terminated NCT02054104 - Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Phase 1/Phase 2
Terminated NCT00706238 - MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma Phase 2
Recruiting NCT04364230 - Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma Phase 1/Phase 2
Active, not recruiting NCT03747744 - Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC) Phase 1
Recruiting NCT03683550 - Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma N/A
Recruiting NCT03620019 - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma Phase 2
Active, not recruiting NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT01667419 - A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma Phase 3
Recruiting NCT04096638 - Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors Phase 1
Completed NCT01118832 - Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi
Not yet recruiting NCT04955743 - Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Phase 2
Not yet recruiting NCT04899492 - Pilot Study in Cancer Patients Scheduled for Surgery Evaluating Different Smoking Cessation Protocols : Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy N/A
Withdrawn NCT03982134 - PDR001 + Panobinostat for Melanoma and NSCLC Phase 1